Evidence map›Paper›PMID 35237503›Full record

ArticleFrontiers in oncology2021

Establishment of an Individualized Predictive Model to Reduce the Core Number for Systematic Prostate Biopsy: A Dual Center Study Based on Stratification of the Disease Risk Score.

Zeyu Chen, Min Qu, Xianqi Shen, Shaoqin Jiang, Wenhui Zhang, Jin Ji, Yan Wang, Jili Zhang, Zhenlin Chen, Lu Lin and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05998278 (Diagnostic Performance of a Individualized Reduced-Core Biopsy Strategy in Prostate Cancer), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05998278 narecruitingnot on this mapstarted 2023, after this paper: background citation

Diagnostic Performance of a Individualized Reduced-Core Biopsy Strategy in Prostate Cancer: A Prospective, Randomized Controlled Study

TypeinterventionalSponsorFujian Medical University Union HospitalRan2023 to 2025Enrolled330ConditionsProstate AdenocarcinomaArmsPersonalized Optimization of Systematic Prostate Biopsy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zeyu ChenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Min QuDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Xianqi ShenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Shaoqin JiangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Wenhui ZhangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jin JiDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yan WangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jili ZhangDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Zhenlin ChenDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, China.
Lu LinDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Mengqiang LiDepartment of Urology, Fujian Union Hospital, Fujian Medical University, Fuzhou, China.
Cheng WuDepartment of Health Statistics, Second Military Medical University, Shanghai, China.
Xu GaoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo establish an individualized prostate biopsy model that reduces unnecessary biopsy cores based on multiparameter MRI (mpMRI). MATERIALS AND

methodsThis retrospective, non-inferiority dual-center study retrospectively included 609 patients from the Changhai Hospital from June 2017 to November 2020 and 431 patients from the Fujian Union Hospital between 2014 and 2019. Clinical, radiological, and pathological data were analyzed. Data from the Changhai Hospital were used for modeling by calculating the patients' disease risk scores. Data from the Fujian Union Hospital were used for external verification.

resultsBased on the data of 609 patients from the Changhai Hospital, we divided the patients evenly into five layers according to the disease risk score. The area under the receiver operating characteristic (ROC) curve (AUC) with 95% confidence intervals (CI) was analyzed. Twelve-core systemic biopsy (12-SBx) was used as the reference standard. The SBx cores from each layer were reduced to 9, 6, 5, 4, and 4. The data of 279 patients with benign pathological results from the Fujian Union Hospital were incorporated into the model. No patients were in the first layer. The accuracies of the models for the other layers were 88, 96.43, 94.87, and 94.59%. The accuracy of each layer would be increased to 96, 100, 100, and 97.30% if the diagnosis of non-clinically significant prostate cancer was excluded.

conclusionsIn this study, we established an individualized biopsy model using data from a dual center. The results showed great accuracy of the model, indicating its future clinical application.

Indexed as

multicenter studymultiparameter MRIPI-RADSpredictive modelsprostate biopsy

Identifiers

PMID35237503
PMCPMC8882832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.